The Professional Ticker Reader ®
Your accurate, authentic and affordable guide to investingVisit our website

Flavours of the week                                                            July 23, 2005

 

These are stocks that we expect to out-perform the markets. Cash and derivative strategies are advised thereon. Please stay online to enable loading of graphics from our servers. Please also read the trading tips section at the end of the newsletter.

Individual stocks.

Ashok Leyland - This scrip was recommended vide our previous editions dtd June 05 & 11, July 02 and 09, 2005. Click here to view the previous recommendations. This scrip was recommended on the basis of a confirmed breakout out of a bearish pattern. As the name suggests, breakout patterns are powerful and relatively safe trading opportunities. The same has been achieved with high volumes and a steep ramp up in the open interest. All of which suggest a build-up in upward momentum. The oscillators are confirming the upmove and the stock may test the previous significant high above 30 levels in the medium term. We remain bullish on the counter and advocate a hold on existing long positions and a buy on declines.

Ashok Leyland - Weekly chart

Your call of action -

  • Investors / cash segment players - hold existing long positions and add on declines to the 25 - 26 levels in case of a fall in the markets. A stop loss at the 23.50 is advised and a projected profit taking target is the 30 level in a few months.

  • Aggressive F&O traders - Buy the August futures ( quoting at Rs 0.50 premium to cash ) on declines to the 26.50 levels and hold with a stop loss at the 24.50 levels. Expect to book profits at the 29.50 - 30.50 levels in the medium term. Due to the size of the market lot, we advocate taking a small / medium sized exposure on this counter.

  • Derivatives contract size - Market lot = 9,550 shares. F&O margin = approx Rs 43,000 (subject to change daily )

Ashok Leyland I Aurobindo Pharma I Canara Bank I Cipla I Dabur Inds I ITC I ONGC I Tata Chem I Tisco I Wockhardt I BSE Sensex I Nifty I CNX-IT I Dow Jones I Nasdaq I FTSE I Top I Close window I Print page

Aurobindo Pharma - This scrip is showing signs of a breakout of a falling channel ( similar to Ashok Leyland above ) and the same has been achieved with high volumes and a positive confirmation from the oscillators. The 375 levels are likely to be a trend determining threshold as the scrip must close above and trade sustainably over this threshold to confirm the upmove. The outlook is positive for the domestic pharma sector and any volatility in the stock markets is likely to benefit the sector due to it's perceived defensive status. There is a positive confirmation from the oscillators which adds to the probability of a rally on this counter. The scrip is a buy on a confirmatory breakout above the 375 levels.

Aurobindo Pharma - Weekly chart

Your call of action -

  • Investors / cash segment players - Buy the scrip after a convincing closing above the 375 levels and hold with a stop loss at the 335 levels. Expect to book profits at the 415 levels partially in the short / medium term and above the 460 mark in the long term.

  • Aggressive F&O traders - Buy the Aug futures ( quoting at Rs 7 premium to cash ) after a convincing breakout above the 380 levels and hold with a stop loss at the 368 level. Expect to book profits in a conducive market at the 410 + levels in the medium term.

  • Derivatives contract size - Market lot = 700 shares. F&O margin = approx Rs 49,000 (subject to change daily )

Ashok Leyland I Aurobindo Pharma I Canara Bank I Cipla I Dabur Inds I ITC I ONGC I Tata Chem I Tisco I Wockhardt I BSE Sensex I Nifty I CNX-IT I Dow Jones I Nasdaq I FTSE I Top I Close window I Print page

Canara Bank - This scrip was recommended vide our previous editions dtd Jan 08, Feb 12, July 09 & 16 2005. Click here to view the previous recommendations. Technical traders will note the scrip moving with a higher tops and bottoms formation within the bullish channel. savvy technical traders will also note the inverted head and shoulder formation in process on the upper trendline. A sustained breakout above the 245 levels with higher volumes will be adequate confirmation of this pattern. Being a measuring move, this pattern enables us to forecast the projected target price of 295 + in a 12 - 15 month time frame, provided the breakout above 245 is sustained on heavy volumes and increase in open interest. The confidence inspiring factors are the oscillators which are in agreement with the price graph and the high relative strength of 233 vis-a-vis the Nifty ( where 100 = base ). We recommend a buy subject to a confirmatory breakout.

Canbank - Weekly chart

Your call of action -

  • Investors / cash segment players - Buy only after the scrip trades sustain ably over the 245 levels and with higher volumes. Maintain a stop loss at the 218 - 220 levels. Expect to book profits at the 285 - 295 levels in a year's time frame.

  • Aggressive F&O traders - Buy the August futures ( quoting at Rs 3.50 discount to cash ) above the 249 level and hold with a stop loss at the 235 level. Expect to book profits at the 265 - 270 levels in the short / medium term. Longer term players may expect higher levels.

  • Derivatives contract size - Market lot = 1,600 shares. F&O margin = approx Rs 59,000 (subject to change daily )

Ashok Leyland I Aurobindo Pharma I Canara Bank I Cipla I Dabur Inds I ITC I ONGC I Tata Chem I Tisco I Wockhardt I BSE Sensex I Nifty I CNX-IT I Dow Jones I Nasdaq I FTSE I Top I Close window I Print page

Cipla - This scrip was recommended vide our previous editions dtd July 02, 09 and 16 2005 and has performed as per our bullish expectations. Click here to view the previous recommendations. We feel the action on the pharma counters is likely to accelerate due to the relatively defensive perception of this segment. Technical traders will note the scrip trading above a significant congestion zone marked by the pink trendline. Serious technicians will also notice an inverted head & shoulder pattern - again a measuring move. Unlike Canara Bank, the breakout above the neckline is complete, volumes are higher and  the open interest has increased - all the factors needed to confirm an uptrend. Note the high relative strength of 569 vis-a-vis the Nifty ( where 100 = base ). We recommend a buy on the counter for the disciplined trader as a breakout of this magnitude often witnesses a pullback downwards, leading to a false sense of threat perception.

Cipla - Weekly chart

Your call of action -

  • Investors / cash segment players - Buy on all dips to the 330 levels in addition to the existing long positions. Maintain a stop loss at the 314 mark and expect to book profits at the 375 levels in the medium term. Longer term players may expect 400 + levels.

  • Aggressive F&O traders - Buy the August futures ( quoting at Rs 2.50 premium to cash ) on all declines to the 330 - 332 levels and hold with a stop loss at the 318 levels. Profit taking is advisable at the 370 - 375 levels in the medium term.

  • Derivatives contract size - Market lot = 1,000 shares. F&O margin = approx Rs 53,000 (subject to change daily )

Ashok Leyland I Aurobindo Pharma I Canara Bank I Cipla I Dabur Inds I ITC I ONGC I Tata Chem I Tisco I Wockhardt I BSE Sensex I Nifty I CNX-IT I Dow Jones I Nasdaq I FTSE I Top I Close window I Print page

Dabur Inds - this scrip was recommended vide earlier newsletters dtd. May 28, June 05 & 11, July 02, July 09 and July 17, 2005 and has performed exactly as per our expectations. Click here to view the previous recommendations. Technical traders may note the already high relative strength of 254 is rising and that too on higher volumes. The scrip is in the second leg of it's upmove and the oscillators are confirming the uptrend. The overall chart pattern imbibes confidence and we suggest a buy on all major declines for the patient and disciplined investors. The upward re-rating of the pharma sector on the whole is likely to help the counter attain higher levels.

Dabur - Weekly chart

Your call of action -

  • Investors / cash segment players - buy the stock on declines to the 140 - 145 levels and leave room for pyramid style averaging till the 130 mark. Maintain a liberal stop loss at the  Expect 118 levels and expect profit taking at the 165 - 170 in the medium term. Long term players may expect higher levels.

  • Aggressive F&O traders - Buy the August futures ( quoting at Rs 2 premium to cash ) on declines to the 145 levels and hold with a stop loss at the 137 levels. Expect to book profit at the 165 + levels in th3e medium term in a conducive market.

  • Derivatives contract size - Market lot = 1,800 shares. F&O margin = approx Rs 52,000 (subject to change daily )

Ashok Leyland I Aurobindo Pharma I Canara Bank I Cipla I Dabur Inds I ITC I ONGC I Tata Chem I Tisco I Wockhardt I BSE Sensex I Nifty I CNX-IT I Dow Jones I Nasdaq I FTSE I Top I Close window I Print page

ITC - This scrip was recommended vide our previous editions dtd Feb 05 & 26, Mar 05, 12 & 25, April 02, 09, 23 & 30, May 07, 14, 21 & 28, June 05, 11, 18 & 25, July 02 & 09, 2005. Click here to view the previous recommendations. This scrip has the pride of place of being the most prolific as also the most profitable recommendation from our side and has rewarded bulls handsomely. We had put out a profit taking recommendation vide sms at the 1789 levels which were projected 3 months in advance. However, we feel the scrip merits investment at lower levels as support would come short covering cum institutional buying. As per retracement studies, a fall to the 1620 levels would be a good fresh entry point for bulls to start nibbling into the counter with a medium term perspective. The relative strength of 325 vis-a-vis the Nifty ( where 100 = base ) is confidence inspiring and we recommend a buy on declines.

ITC - Weekly chart

Your call of action -

  • Investors / cash segment players - Buy on declines to the 1600 - 1620 levels and keep room for pyramid averaging till the 1545 levels. Maintain a stop loss at the 1490 levels and expect to book profits partially at the 1750 levels. Total profit taking is advocated at the 1845 - 1865 levels in the medium / long term.

  • Aggressive F&O traders - Buy the Aug futures ( quoting at Rs 16 premium to cash ) at the 1635 - 1645 levels and average lower till the 1605 levels. A stop loss at the 1555 - 1560 is advised and a profit taking targets are the 1740 - 1750 levels in the medium term.

  • Derivatives contract size - Market lot = 150 shares. F&O margin = approx Rs 39,000 (subject to change daily )

Ashok Leyland I Aurobindo Pharma I Canara Bank I Cipla I Dabur Inds I ITC I ONGC I Tata Chem I Tisco I Wockhardt I BSE Sensex I Nifty I CNX-IT I Dow Jones I Nasdaq I FTSE I Top I Close window I Print page

ONGC - This scrip was recommended vide our previous editions dtd. June 25 and July 02 & 09, 2005. Click here to view the previous recommendations. The stock has not performed up to our expectations as the newsflow on subsidy burden sharing created excessive volatility on the counter. We feel the scrip is unlikely to move below the 893 levels which corresponds with the 61.80 % retracement levels on the short term charts. The short term oscillators are pointing towards a build up in upward momentum and a buy is recommended for higher risk / aggressive short term traders.

ONGC - Daily chart

Your call of action -

  • Investors / cash segment players - Buy at the 925 - 930 levels and hold with a stop loss at the 893 mark. Expect to book profits at the 962 levels partially and the 990 + levels completely in the short / medium term in a conducive market scenario. Traders must also keep monitoring the crude oil prices in tandem with the ONGC scrip.

  • Aggressive F&O traders - Buy the Aug futures ( quoting at Re 1 discount to cash ) at the current levels and hold with a stop loss at the 916 levels. Expect profit taking at the 965 levels in the short term and 980 - 990 in the medium term.

  • Derivatives contract size - Market lot = 300 shares. F&O margin = approx Rs 44,000 (subject to change daily )

Ashok Leyland I Aurobindo Pharma I Canara Bank I Cipla I Dabur Inds I ITC I ONGC I Tata Chem I Tisco I Wockhardt I BSE Sensex I Nifty I CNX-IT I Dow Jones I Nasdaq I FTSE I Top I Close window I Print page

Tata Chem This scrip was recommended vide our previous editions dtd July 16 2005 and has appreciated since the buy call. Click here to view the previous recommendations. The scrip is in a bull grip and the second phase of it's upmove which is likely to exhaust at the 225 - 229 levels which were advocated earlier. The directional movement oscillator is signalling a buildup of momentum and the traded volumes have jumped sharply. We recommend a buy on declines for patient trader / investor.

Tata Chem - Weekly chart

Your call of action -

  • Investors / cash segment players - Buy on declines to the 180 - 185 levels and average in pyramid fashion till the 170 level. Maintain a stop loss at the 160 and expect to book profits at the 225 - 228 levels.

  • Aggressive F&O traders - Buy the Aug futures ( quoting at Rs 2 premium to cash ) at the 188 level and hold with a stop loss at the 181 level. Expect to book profit at the 220 + mark in the medium term.

  • Derivatives contract size - Market lot = 1,350 shares. F&O margin = approx Rs 44,000 (subject to change daily )

Ashok Leyland I Aurobindo Pharma I Canara Bank I Cipla I Dabur Inds I ITC I ONGC I Tata Chem I Tisco I Wockhardt I BSE Sensex I Nifty I CNX-IT I Dow Jones I Nasdaq I FTSE I Top I Close window I Print page

TiscoThis scrip was recommended vide our previous editions dtd Jan 15, 21 & 29, Feb 19 & 26, March 05 & 12 and June 11, 2005 and has been a mixed bag of results. Click here to view the previous recommendations. After a prolonged fall, the stock is showing signs of bottoming out as the scrip makes a higher tops and bottoms formations. The traded volumes have perked up in the last week and the momentum oscillators are showing a build-up of upward momentum. Technical savvy traders will note the inverted head and shoulders formation with the neckline at the 364 mark. Being a measuring move, it is possible to foresee a target of 390 - 395 in the medium term as long as the neckline is not violated with higher volumes. Please note - it is routine for a head and shoulder pattern to witness a retracement to the neckline ( currently at the 364 levels ) after a breakout so panic termination of long trades is not advisable.

Tisco - Daily chart

Your call of action -

  • Investors / cash segment players - Buy on declines to the 370 level and hold with a stop loss at the 362 mark on a closing basis. Expect to book profits at the 388 - 395 in the short / medium term in a bullish market scenario.

  • Aggressive F&O traders - Buy the Aug futures ( quoting at Rs 4 premium to cash ) at the 372 - 374 levels and hold with a stop loss at the 366 mark. Expect profit taking at the 390 levels in the short term.

  • Derivatives contract size - Market lot = 675 shares. F&O margin = approx Rs 40,000 (subject to change daily )

Ashok Leyland I Aurobindo Pharma I Canara Bank I Cipla I Dabur Inds I ITC I ONGC I Tata Chem I Tisco I Wockhardt I BSE Sensex I Nifty I CNX-IT I Dow Jones I Nasdaq I FTSE I Top I Close window I Print page

Wockhardt - This scrip is in a strong upmove as the chart shows a text book style rising tops and bottoms formation with volumes perking up recently. Currently in the second phase of the upmove, the scrip is likely to gat support at the 405 levels and may see the rally extending to the 520 levels in the medium term. The scrip is a market out-performer and the oscillators are indicating a bullish outlook. Buy on all major declines.

Wockhardt - Weekly chart

Your call of action -

  • Investors / cash segment players - Buy at lower levels of 430 - 440 and average lower in pyramid formation till the 410 levels. Maintain a stop loss at the 375 - 380 levels and expect to book profits at the 525 mark in the medium term. Long term players may expect higher levels.

  • Aggressive F&O traders - Buy the August futures ( quoting at Rs 4 premium to cash ) at the 445 - 450 levels and average lower till the 420 mark. Hold with a stop loss at the 405 level and expect profit taking at the 500 + levels in the medium term.

  • Derivatives contract size - Market lot = 600 shares. F&O margin = approx Rs 47,000 (subject to change daily )

Ashok Leyland I Aurobindo Pharma I Canara Bank I Cipla I Dabur Inds I ITC I ONGC I Tata Chem I Tisco I Wockhardt I BSE Sensex I Nifty I CNX-IT I Dow Jones I Nasdaq I FTSE I Top I Close window I Print page

Indices - domestic

BSE Sensex - this BSE benchmark is in a new trading zone as the closing is at it's lifetime highs. The oscillators are supporting the upmove and the index may scale the 7565 level in the coming week. We feel the downsides are likely to be limited to the 7190 mark in the extreme scenario.

BSE Sensex - Daily chart

Your call of action - Since the Sensex futures are not very liquid, we suggest trading  the Nifty 50  instead.

Ashok Leyland I Aurobindo Pharma I Canara Bank I Cipla I Dabur Inds I ITC I ONGC I Tata Chem I Tisco I Wockhardt I BSE Sensex I Nifty I CNX-IT I Dow Jones I Nasdaq I FTSE I Top I Close window I Print page

Nifty 50 - This NSE index is also at it's lifetime highs and has closed comfortable above the 2249 levels. The bullish channel though violated twice in as many weeks has still held and the next resistance is likely at the 2283 and then the 2337 mark in the coming weeks. Support is likely at the 2239 and then at the 2218 mark. We maintain a bullish bias.

Nifty 50 - Daily chart

Your call of action - buy long at the current levels if you are a higher risk appetite trader and hold with a stop loss at the 2239. Expect profit taking near the 2283 / 2295 mark in the near term. Traded quantities must be curtailed due to higher volatility expected.

Ashok Leyland I Aurobindo Pharma I Canara Bank I Cipla I Dabur Inds I ITC I ONGC I Tata Chem I Tisco I Wockhardt I BSE Sensex I Nifty I CNX-IT I Dow Jones I Nasdaq I FTSE I Top I Close window I Print page

CNX IT - this technology index has recovered in the previous week after a brief fall to the short term moving averages. Though this index has been a out-performer vis-a-vis the Nifty 50, the edge is clearly getting blunt as the composite scrips succumb to profit taking pressures. Only a sustained trade above the 3000 levels will see a trend reversal and a bullish outlook return to this index.

CNX IT - Daily chart

Your call of action - Since the CNX IT futures are not very liquid, we suggest trading the Nifty 50 instead.

Ashok Leyland I Aurobindo Pharma I Canara Bank I Cipla I Dabur Inds I ITC I ONGC I Tata Chem I Tisco I Wockhardt I BSE Sensex I Nifty I CNX-IT I Dow Jones I Nasdaq I FTSE I Top I Close window I Print page

Indices - international

Dow Jones Industrial Average - this NYSE old economy index is trading at the 6 month highs and shows signs of consolidation as the momentum is flagging. The outlook will remain bullish as long as the 10,600 remain un-violated. The upsides may see the 10770 - 10800 being tested.

Dow Jones - Daily chart

Your call of action - this is a pure academic study.

Ashok Leyland I Aurobindo Pharma I Canara Bank I Cipla I Dabur Inds I ITC I ONGC I Tata Chem I Tisco I Wockhardt I BSE Sensex I Nifty I CNX-IT I Dow Jones I Nasdaq I FTSE I Top I Close window I Print page

Nasdaq - this technology index is out performing the Dow Jones index and the short term support is at the 2130 levels. As long as the 2100 levels are not violated, the outlook will remain positive. Upsides will see minor resistance at the 2198 levels and 2220 level will be a formidable hurdle. The outlook remains positive.

Nasdaq - Daily chart

Your call of action - this is a pure academic study.

Ashok Leyland I Aurobindo Pharma I Canara Bank I Cipla I Dabur Inds I ITC I ONGC I Tata Chem I Tisco I Wockhardt I BSE Sensex I Nifty I CNX-IT I Dow Jones I Nasdaq I FTSE I Top I Close window I Print page

FTSE - this UK index is trading at 3 year highs and is likely to witness support at the 5140 levels. As long as this level is not violated, expect the uptrend to remain intact. Minor resistance at the 5285 will be seen and above this level, the upmove maybe accelerated.

FTSE - Daily chart

Your call of action - this is a pure academic study.

Ashok Leyland I Aurobindo Pharma I Canara Bank I Cipla I Dabur Inds I ITC I ONGC I Tata Chem I Tisco I Wockhardt I BSE Sensex I Nifty I CNX-IT I Dow Jones I Nasdaq I FTSE I Top I Close window I Print page

Trading tips for the  week

  • The put / call ratio is climbing and is currently at the 0.37 : 1 levels and the outstanding positions in the derivatives segment have shown a qualitative increase. The FII investments are continuing steadily.

  • The index heavy-weights are showing strength again. This in turn will boost the indices and cause a feel good factor. The only worry is that this upbeat sentiment should continue in the face of terror attacks and negative newsflow.

  • The impeding expiry of the July series will see offloading and higher volatility in the near term.

  • Trades must be executed in small volumes due to the higher volatility expected. Trade fewer counters and conserve cash for future opportunities.

  • Standby for fresh recommendations via SMS on a real - time basis.

Have a  profitable week.
 
Vijay L Bhambwani
Ceo :- Bsplindia.com

The  author is a Mumbai  based investment consultant and  invites feedback at Vijay@BSPLindia.com and  ( 022 ) 23438482 / 23400345.

SEBI  disclosure :-  The  author has no positions in any securities mentioned  above.


Legal  notice :-  The Professional  Ticker Reader is  a  trademark  of  Bhambwani  Securities (P) Ltd.  and  any un-authorised  replication / duplication  in part or full  will  be  infringing  our  trademark and  will  result  in legal  action  being  enforced  on  the  infringing  persons / parties.


While all due care has been taken while in compiling the data enclosed herein, we cannot be held responsible for errors, if any, creeping in. Please  consult  an  independent  qualified  investment  advisor before  taking  investment  decisions. This mail is not sent unsolicited, and only advisory in nature. We have accepted no consideration from any company mentioned above and recommend taking decisions on merits of the stocks from our viewpoint. This email is being sent to you as a paid subscriber. Please protect your interests and ours by not disclosing the contents to any un-authorised  person/s